This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04951/identifier/chemspider/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB04951/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04951/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04951/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04951
rdf:type
n3:Drug
n3:description
Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
n3:dosage
n15:271B60BB-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG: Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun. 2002 Jun;70(6):2989-94. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12010989 # Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F: Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007 Oct;47(10):1268-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17906160
n3:group
investigational
n3:halfLife
2-2.5 hours
n3:indication
For the treatment of idiopathic pulmonary fibrosis (IPF).
owl:sameAs
n12:DB04951
dcterms:title
Pirfenidone
adms:identifier
n6:40632 n7:11111619 n8:37115 n9:DB04951
n3:mechanismOfAction
Pirfenidone is an orally active, small molecule that shows a wide range of biologic activity. In vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Pirfenidone leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin. In addition, pirfenidone reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis.
n3:toxicity
Generally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.
n3:IUPAC-Name
n4:271B60C0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B60C6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B60C5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B60C2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B60C3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B60C4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B60BE-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B60BF-363D-11E5-9242-09173F13E4C5 n4:271B60BC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B60BD-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:L04AX05
n3:H-Bond-Acceptor-Count
n4:271B60CC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B60CD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B60C7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B60C8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B60CA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B60C9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B60CB-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53179-13-8
n3:Bioavailability
n4:271B60D1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B60D3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B60D4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B60D0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B60CF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B60D2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B60C1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B60CE-363D-11E5-9242-09173F13E4C5